Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Active, not recruiting · NCT05033756 · Registry updated 2024-05-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2024-05-07 | NCT05033756 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institut fuer Frauengesundheit | 6 |
| Merck Sharp & Dohme LLC | 650 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Gynecology and Obstetrics, Erlangen University Hospital | Erlangen | Germany | 2 |
| Department of Gynecology, Tübingen University Hospital | Tübingen | Germany | 1 |
| Helios-Klinikum Berlin-Buch | Berlin | Germany | 1 |
| Marienhospital Bottrop | Bottrop | Germany | 1 |
| University Hospital Düsseldorf | Düsseldorf | Germany | 10 |
| University Hospital Ulm | Ulm | Germany | 1 |